Use of Paclitaxel in ovarian cancer is justified

The congratulations offered by Dr Harding to those health authorities yet to make Paclitaxel available to their patients with ovarian cancer are misplaced. The evidence was summarised in Effective Health Care and is set out more fully in the research evidence volume of the Guidance on Commissioning Cancer Services - ...

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here